The impact of IL-1 modulation on the development of lipopolysaccharide-induced cognitive dysfunction
The impact of pro-inflammatory cytokines on neuroinflammation and cognitive function after lipopolysaccharide (LPS) challenge remains elusive. Herein we provide evidence that there is a temporal correlation between high-mobility group box 1 (HMGB-1), microglial activation, and cognitive dysfunction....
Gespeichert in:
Veröffentlicht in: | Critical care (London, England) England), 2010-01, Vol.14 (3), p.R88-R88, Article R88 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | R88 |
---|---|
container_issue | 3 |
container_start_page | R88 |
container_title | Critical care (London, England) |
container_volume | 14 |
creator | Terrando, Niccolò Rei Fidalgo, António Vizcaychipi, Marcela Cibelli, Mario Ma, Daqing Monaco, Claudia Feldmann, Marc Maze, Mervyn |
description | The impact of pro-inflammatory cytokines on neuroinflammation and cognitive function after lipopolysaccharide (LPS) challenge remains elusive. Herein we provide evidence that there is a temporal correlation between high-mobility group box 1 (HMGB-1), microglial activation, and cognitive dysfunction. Disabling the interleukin (IL)-1 signaling pathway is sufficient to reduce inflammation and ameliorate the disability.
Endotoxemia was induced in wild-type and IL-1R-/- mice by intra peritoneal injection of E. Coli LPS (1 mg/kg). Markers of inflammation were assessed both peripherally and centrally, and correlated to behavioral outcome using trace fear conditioning.
Increase in plasma tumor necrosis factor-alpha (TNFalpha) peaked at 30 minutes after LPS challenge. Up-regulation of IL-1beta, IL-6 and HMGB-1 was more persistent, with detectable levels up to day three. A 15-fold increase in IL-6 and a 6.5-fold increase in IL-1beta mRNA at 6 hours post intervention (P < 0.001 respectively) was found in the hippocampus. Reactive microgliosis was observed both at days one and three, and was associated with elevated HMGB-1 and impaired memory retention (P < 0.005). Preemptive administration of IL-1 receptor antagonist (IL-1Ra) significantly reduced plasma cytokines and hippocampal microgliosis and ameliorated cognitive dysfunction without affecting HMGB-1 levels. Similar results were observed in LPS-challenged mice lacking the IL-1 receptor to those seen in LPS-challenged wild type mice treated with IL-1Ra.
These data suggest that by blocking IL-1 signaling, the inflammatory cascade to LPS is attenuated, thereby reducing microglial activation and preventing the behavioral abnormality. |
doi_str_mv | 10.1186/cc9019 |
format | Article |
fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2911722</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A229108334</galeid><sourcerecordid>A229108334</sourcerecordid><originalsourceid>FETCH-LOGICAL-b607t-8e96af79caa379390fa4577d1f8c6bba188ebd852bc27053721b1c6f47c79cc3</originalsourceid><addsrcrecordid>eNp1kltrHCEYhofS0hza_oQytJBeTaqjo85NIYQeAgu52YvcifOpuwZHp-PMwv77up0k7ZYGBUWf9_0OWhTvMLrEWLDPAC3C7YviFFPGKobau5d5TxitREOak-IspXuEMBeMvC5OakQ5ooidFnq9NaXrBwVTGW15s6pw2Uc9ezW5GMo8pwxoszM-Dr0JvynvhjhEv08KYKtGp03lgp7B6BLiJrjJ7bJmn-wc4GDzpnhllU_m7cN6Xqy_fV1f_6hWt99vrq9WVccQnyphWqYsb0EpwlvSIqtow7nGVgDrOoWFMJ0WTd1BzVFDeI07DMxSDlkE5Lz4stgOc9cbDTnbUXk5jK5X415G5eTxTXBbuYk7WbcY87rOBu1i0Ln4jMHxDcReLp3P2k8Pwcf4czZpkr1LYLxXwcQ5Sd7QpiGkxpn88A95H-cx5MZITihF-W2aDH1coI3yRrpgYw4IB0t5Ved8kSCEZuryP1Qe2vQOYjDW5fMjwcUigDGmNBr7VBxG8vCR_pTz_u9ePmGPP4f8ArenxOc</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>734400475</pqid></control><display><type>article</type><title>The impact of IL-1 modulation on the development of lipopolysaccharide-induced cognitive dysfunction</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><source>Springer Nature OA/Free Journals</source><source>SpringerLink Journals - AutoHoldings</source><creator>Terrando, Niccolò ; Rei Fidalgo, António ; Vizcaychipi, Marcela ; Cibelli, Mario ; Ma, Daqing ; Monaco, Claudia ; Feldmann, Marc ; Maze, Mervyn</creator><creatorcontrib>Terrando, Niccolò ; Rei Fidalgo, António ; Vizcaychipi, Marcela ; Cibelli, Mario ; Ma, Daqing ; Monaco, Claudia ; Feldmann, Marc ; Maze, Mervyn</creatorcontrib><description>The impact of pro-inflammatory cytokines on neuroinflammation and cognitive function after lipopolysaccharide (LPS) challenge remains elusive. Herein we provide evidence that there is a temporal correlation between high-mobility group box 1 (HMGB-1), microglial activation, and cognitive dysfunction. Disabling the interleukin (IL)-1 signaling pathway is sufficient to reduce inflammation and ameliorate the disability.
Endotoxemia was induced in wild-type and IL-1R-/- mice by intra peritoneal injection of E. Coli LPS (1 mg/kg). Markers of inflammation were assessed both peripherally and centrally, and correlated to behavioral outcome using trace fear conditioning.
Increase in plasma tumor necrosis factor-alpha (TNFalpha) peaked at 30 minutes after LPS challenge. Up-regulation of IL-1beta, IL-6 and HMGB-1 was more persistent, with detectable levels up to day three. A 15-fold increase in IL-6 and a 6.5-fold increase in IL-1beta mRNA at 6 hours post intervention (P < 0.001 respectively) was found in the hippocampus. Reactive microgliosis was observed both at days one and three, and was associated with elevated HMGB-1 and impaired memory retention (P < 0.005). Preemptive administration of IL-1 receptor antagonist (IL-1Ra) significantly reduced plasma cytokines and hippocampal microgliosis and ameliorated cognitive dysfunction without affecting HMGB-1 levels. Similar results were observed in LPS-challenged mice lacking the IL-1 receptor to those seen in LPS-challenged wild type mice treated with IL-1Ra.
These data suggest that by blocking IL-1 signaling, the inflammatory cascade to LPS is attenuated, thereby reducing microglial activation and preventing the behavioral abnormality.</description><identifier>ISSN: 1364-8535</identifier><identifier>EISSN: 1466-609X</identifier><identifier>EISSN: 1364-8535</identifier><identifier>DOI: 10.1186/cc9019</identifier><identifier>PMID: 20470406</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Animals ; Biological markers ; Cognition disorders ; Cognition Disorders - chemically induced ; Cognition Disorders - immunology ; Cognition Disorders - prevention & control ; Critical care medicine ; Cytokines - blood ; Endotoxemia - chemically induced ; Endotoxemia - metabolism ; Escherichia coli ; Escherichia coli - immunology ; Escherichia coli - metabolism ; Genetic aspects ; Hippocampus - metabolism ; HMGB1 Protein - metabolism ; Identification and classification ; Interleukin-1 ; Interleukin-1 - antagonists & inhibitors ; Interleukin-1 - genetics ; Interleukin-1 - pharmacology ; Lipopolysaccharides ; Lipopolysaccharides - administration & dosage ; Lipopolysaccharides - adverse effects ; Mice ; Mice, Inbred C57BL ; Microglia - metabolism ; Properties ; Risk factors ; Tumor Necrosis Factor-alpha - blood ; Tumor Necrosis Factor-alpha - drug effects</subject><ispartof>Critical care (London, England), 2010-01, Vol.14 (3), p.R88-R88, Article R88</ispartof><rights>COPYRIGHT 2010 BioMed Central Ltd.</rights><rights>Copyright National Library of Medicine - MEDLINE Abstracts 2010</rights><rights>Copyright ©2010 Terrando et al.; licensee BioMed Central Ltd. 2010 Terrando et al.; licensee BioMed Central Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b607t-8e96af79caa379390fa4577d1f8c6bba188ebd852bc27053721b1c6f47c79cc3</citedby><cites>FETCH-LOGICAL-b607t-8e96af79caa379390fa4577d1f8c6bba188ebd852bc27053721b1c6f47c79cc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2911722/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2911722/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20470406$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Terrando, Niccolò</creatorcontrib><creatorcontrib>Rei Fidalgo, António</creatorcontrib><creatorcontrib>Vizcaychipi, Marcela</creatorcontrib><creatorcontrib>Cibelli, Mario</creatorcontrib><creatorcontrib>Ma, Daqing</creatorcontrib><creatorcontrib>Monaco, Claudia</creatorcontrib><creatorcontrib>Feldmann, Marc</creatorcontrib><creatorcontrib>Maze, Mervyn</creatorcontrib><title>The impact of IL-1 modulation on the development of lipopolysaccharide-induced cognitive dysfunction</title><title>Critical care (London, England)</title><addtitle>Crit Care</addtitle><description>The impact of pro-inflammatory cytokines on neuroinflammation and cognitive function after lipopolysaccharide (LPS) challenge remains elusive. Herein we provide evidence that there is a temporal correlation between high-mobility group box 1 (HMGB-1), microglial activation, and cognitive dysfunction. Disabling the interleukin (IL)-1 signaling pathway is sufficient to reduce inflammation and ameliorate the disability.
Endotoxemia was induced in wild-type and IL-1R-/- mice by intra peritoneal injection of E. Coli LPS (1 mg/kg). Markers of inflammation were assessed both peripherally and centrally, and correlated to behavioral outcome using trace fear conditioning.
Increase in plasma tumor necrosis factor-alpha (TNFalpha) peaked at 30 minutes after LPS challenge. Up-regulation of IL-1beta, IL-6 and HMGB-1 was more persistent, with detectable levels up to day three. A 15-fold increase in IL-6 and a 6.5-fold increase in IL-1beta mRNA at 6 hours post intervention (P < 0.001 respectively) was found in the hippocampus. Reactive microgliosis was observed both at days one and three, and was associated with elevated HMGB-1 and impaired memory retention (P < 0.005). Preemptive administration of IL-1 receptor antagonist (IL-1Ra) significantly reduced plasma cytokines and hippocampal microgliosis and ameliorated cognitive dysfunction without affecting HMGB-1 levels. Similar results were observed in LPS-challenged mice lacking the IL-1 receptor to those seen in LPS-challenged wild type mice treated with IL-1Ra.
These data suggest that by blocking IL-1 signaling, the inflammatory cascade to LPS is attenuated, thereby reducing microglial activation and preventing the behavioral abnormality.</description><subject>Animals</subject><subject>Biological markers</subject><subject>Cognition disorders</subject><subject>Cognition Disorders - chemically induced</subject><subject>Cognition Disorders - immunology</subject><subject>Cognition Disorders - prevention & control</subject><subject>Critical care medicine</subject><subject>Cytokines - blood</subject><subject>Endotoxemia - chemically induced</subject><subject>Endotoxemia - metabolism</subject><subject>Escherichia coli</subject><subject>Escherichia coli - immunology</subject><subject>Escherichia coli - metabolism</subject><subject>Genetic aspects</subject><subject>Hippocampus - metabolism</subject><subject>HMGB1 Protein - metabolism</subject><subject>Identification and classification</subject><subject>Interleukin-1</subject><subject>Interleukin-1 - antagonists & inhibitors</subject><subject>Interleukin-1 - genetics</subject><subject>Interleukin-1 - pharmacology</subject><subject>Lipopolysaccharides</subject><subject>Lipopolysaccharides - administration & dosage</subject><subject>Lipopolysaccharides - adverse effects</subject><subject>Mice</subject><subject>Mice, Inbred C57BL</subject><subject>Microglia - metabolism</subject><subject>Properties</subject><subject>Risk factors</subject><subject>Tumor Necrosis Factor-alpha - blood</subject><subject>Tumor Necrosis Factor-alpha - drug effects</subject><issn>1364-8535</issn><issn>1466-609X</issn><issn>1364-8535</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kltrHCEYhofS0hza_oQytJBeTaqjo85NIYQeAgu52YvcifOpuwZHp-PMwv77up0k7ZYGBUWf9_0OWhTvMLrEWLDPAC3C7YviFFPGKobau5d5TxitREOak-IspXuEMBeMvC5OakQ5ooidFnq9NaXrBwVTGW15s6pw2Uc9ezW5GMo8pwxoszM-Dr0JvynvhjhEv08KYKtGp03lgp7B6BLiJrjJ7bJmn-wc4GDzpnhllU_m7cN6Xqy_fV1f_6hWt99vrq9WVccQnyphWqYsb0EpwlvSIqtow7nGVgDrOoWFMJ0WTd1BzVFDeI07DMxSDlkE5Lz4stgOc9cbDTnbUXk5jK5X415G5eTxTXBbuYk7WbcY87rOBu1i0Ln4jMHxDcReLp3P2k8Pwcf4czZpkr1LYLxXwcQ5Sd7QpiGkxpn88A95H-cx5MZITihF-W2aDH1coI3yRrpgYw4IB0t5Ved8kSCEZuryP1Qe2vQOYjDW5fMjwcUigDGmNBr7VBxG8vCR_pTz_u9ePmGPP4f8ArenxOc</recordid><startdate>20100101</startdate><enddate>20100101</enddate><creator>Terrando, Niccolò</creator><creator>Rei Fidalgo, António</creator><creator>Vizcaychipi, Marcela</creator><creator>Cibelli, Mario</creator><creator>Ma, Daqing</creator><creator>Monaco, Claudia</creator><creator>Feldmann, Marc</creator><creator>Maze, Mervyn</creator><general>BioMed Central Ltd</general><general>National Library of Medicine - MEDLINE Abstracts</general><general>BioMed Central</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7T5</scope><scope>7TK</scope><scope>H94</scope><scope>5PM</scope></search><sort><creationdate>20100101</creationdate><title>The impact of IL-1 modulation on the development of lipopolysaccharide-induced cognitive dysfunction</title><author>Terrando, Niccolò ; Rei Fidalgo, António ; Vizcaychipi, Marcela ; Cibelli, Mario ; Ma, Daqing ; Monaco, Claudia ; Feldmann, Marc ; Maze, Mervyn</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b607t-8e96af79caa379390fa4577d1f8c6bba188ebd852bc27053721b1c6f47c79cc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Animals</topic><topic>Biological markers</topic><topic>Cognition disorders</topic><topic>Cognition Disorders - chemically induced</topic><topic>Cognition Disorders - immunology</topic><topic>Cognition Disorders - prevention & control</topic><topic>Critical care medicine</topic><topic>Cytokines - blood</topic><topic>Endotoxemia - chemically induced</topic><topic>Endotoxemia - metabolism</topic><topic>Escherichia coli</topic><topic>Escherichia coli - immunology</topic><topic>Escherichia coli - metabolism</topic><topic>Genetic aspects</topic><topic>Hippocampus - metabolism</topic><topic>HMGB1 Protein - metabolism</topic><topic>Identification and classification</topic><topic>Interleukin-1</topic><topic>Interleukin-1 - antagonists & inhibitors</topic><topic>Interleukin-1 - genetics</topic><topic>Interleukin-1 - pharmacology</topic><topic>Lipopolysaccharides</topic><topic>Lipopolysaccharides - administration & dosage</topic><topic>Lipopolysaccharides - adverse effects</topic><topic>Mice</topic><topic>Mice, Inbred C57BL</topic><topic>Microglia - metabolism</topic><topic>Properties</topic><topic>Risk factors</topic><topic>Tumor Necrosis Factor-alpha - blood</topic><topic>Tumor Necrosis Factor-alpha - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Terrando, Niccolò</creatorcontrib><creatorcontrib>Rei Fidalgo, António</creatorcontrib><creatorcontrib>Vizcaychipi, Marcela</creatorcontrib><creatorcontrib>Cibelli, Mario</creatorcontrib><creatorcontrib>Ma, Daqing</creatorcontrib><creatorcontrib>Monaco, Claudia</creatorcontrib><creatorcontrib>Feldmann, Marc</creatorcontrib><creatorcontrib>Maze, Mervyn</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Critical care (London, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Terrando, Niccolò</au><au>Rei Fidalgo, António</au><au>Vizcaychipi, Marcela</au><au>Cibelli, Mario</au><au>Ma, Daqing</au><au>Monaco, Claudia</au><au>Feldmann, Marc</au><au>Maze, Mervyn</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The impact of IL-1 modulation on the development of lipopolysaccharide-induced cognitive dysfunction</atitle><jtitle>Critical care (London, England)</jtitle><addtitle>Crit Care</addtitle><date>2010-01-01</date><risdate>2010</risdate><volume>14</volume><issue>3</issue><spage>R88</spage><epage>R88</epage><pages>R88-R88</pages><artnum>R88</artnum><issn>1364-8535</issn><eissn>1466-609X</eissn><eissn>1364-8535</eissn><abstract>The impact of pro-inflammatory cytokines on neuroinflammation and cognitive function after lipopolysaccharide (LPS) challenge remains elusive. Herein we provide evidence that there is a temporal correlation between high-mobility group box 1 (HMGB-1), microglial activation, and cognitive dysfunction. Disabling the interleukin (IL)-1 signaling pathway is sufficient to reduce inflammation and ameliorate the disability.
Endotoxemia was induced in wild-type and IL-1R-/- mice by intra peritoneal injection of E. Coli LPS (1 mg/kg). Markers of inflammation were assessed both peripherally and centrally, and correlated to behavioral outcome using trace fear conditioning.
Increase in plasma tumor necrosis factor-alpha (TNFalpha) peaked at 30 minutes after LPS challenge. Up-regulation of IL-1beta, IL-6 and HMGB-1 was more persistent, with detectable levels up to day three. A 15-fold increase in IL-6 and a 6.5-fold increase in IL-1beta mRNA at 6 hours post intervention (P < 0.001 respectively) was found in the hippocampus. Reactive microgliosis was observed both at days one and three, and was associated with elevated HMGB-1 and impaired memory retention (P < 0.005). Preemptive administration of IL-1 receptor antagonist (IL-1Ra) significantly reduced plasma cytokines and hippocampal microgliosis and ameliorated cognitive dysfunction without affecting HMGB-1 levels. Similar results were observed in LPS-challenged mice lacking the IL-1 receptor to those seen in LPS-challenged wild type mice treated with IL-1Ra.
These data suggest that by blocking IL-1 signaling, the inflammatory cascade to LPS is attenuated, thereby reducing microglial activation and preventing the behavioral abnormality.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>20470406</pmid><doi>10.1186/cc9019</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1364-8535 |
ispartof | Critical care (London, England), 2010-01, Vol.14 (3), p.R88-R88, Article R88 |
issn | 1364-8535 1466-609X 1364-8535 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2911722 |
source | MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Alma/SFX Local Collection; Springer Nature OA/Free Journals; SpringerLink Journals - AutoHoldings |
subjects | Animals Biological markers Cognition disorders Cognition Disorders - chemically induced Cognition Disorders - immunology Cognition Disorders - prevention & control Critical care medicine Cytokines - blood Endotoxemia - chemically induced Endotoxemia - metabolism Escherichia coli Escherichia coli - immunology Escherichia coli - metabolism Genetic aspects Hippocampus - metabolism HMGB1 Protein - metabolism Identification and classification Interleukin-1 Interleukin-1 - antagonists & inhibitors Interleukin-1 - genetics Interleukin-1 - pharmacology Lipopolysaccharides Lipopolysaccharides - administration & dosage Lipopolysaccharides - adverse effects Mice Mice, Inbred C57BL Microglia - metabolism Properties Risk factors Tumor Necrosis Factor-alpha - blood Tumor Necrosis Factor-alpha - drug effects |
title | The impact of IL-1 modulation on the development of lipopolysaccharide-induced cognitive dysfunction |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T06%3A26%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20impact%20of%20IL-1%20modulation%20on%20the%20development%20of%20lipopolysaccharide-induced%20cognitive%20dysfunction&rft.jtitle=Critical%20care%20(London,%20England)&rft.au=Terrando,%20Niccol%C3%B2&rft.date=2010-01-01&rft.volume=14&rft.issue=3&rft.spage=R88&rft.epage=R88&rft.pages=R88-R88&rft.artnum=R88&rft.issn=1364-8535&rft.eissn=1466-609X&rft_id=info:doi/10.1186/cc9019&rft_dat=%3Cgale_pubme%3EA229108334%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=734400475&rft_id=info:pmid/20470406&rft_galeid=A229108334&rfr_iscdi=true |